Cantoni Therapeutics BV has announced the closing of additional financing to advance its lead asset into IND-enabling studies for obesity and its comorbidities. The company is developing small-molecule inhibitors of nicotinamide N-methyltransferase (NNMT), a promising target for cardiometabolic diseases. Cantoni has also won a Novo Nordisk ValidatioNN grant supporting translational research work on the mode of action of NNMT inhibition.
Rona Therapeutics Co. Ltd. has announced an IND filing with the Australian Human Research Ethics Committee (HREC) for RN-3161 for obesity. RN-3161, a novel siRNA developed through Rona’s proprietary GAIA platform, targets INHBE to reduce fat while preserving lean mass.
Shanghai Yidi Biotechnology Co. Ltd. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of diabetes.
Rezubio Pharmaceuticals Co. Ltd. has disclosed drug conjugates comprising somatostatin receptor type 5 (SSTR5) antagonists covalently linked to a hydrophilic moiety through a linker reported to be useful for the treatment of type 2 diabetes.
Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to their complementary mechanisms of action. GPR119 agonists stimulate glucose-dependent insulin secretion, while DPP-4 inhibitors enhance the duration of incretin hormone activity by preventing their degradation. Together, these mechanisms contribute to improved glycemic control in individuals with T2D.
Suzhou Puhe Biopharma Co. Ltd. has described apelin receptor (APLNR) agonists reported to be useful for the treatment of idiopathic pulmonary fibrosis, diabetes, obesity, heart failure, hypertension, pulmonary hypertension, sarcopenia and scleroderma.
Maze Therapeutics Inc. CEO Jason Coloma said the latest phase I results with MZE-782, a prospect for phenylketonuria (PKU) as well as chronic kidney disease (CKD), bolster the firm’s “conviction to move into phase II” next year in both indications.
Chong Kun Dang Pharmaceutical Corp. has prepared and tested glucagon-like peptide 1 receptor (GLP-1R) agonists reported to be useful for the treatment of fibrosis, neurodegeneration, nutrition, endocrine, immunological, inflammatory, psychiatric and renal disorders, among others.
The U.S. FDA issued a complete response letter (CRL) for the NDA to privately held Saol Therapeutics Inc.’s rare disease treatment, sodium dichloroacetate (SL-1009), for pyruvate dehydrogenase complex deficiency. The inhibitor of pyruvate dehydrogenase kinases is the only drug in development for treating the rare genetic disorder, according to Cortellis. There are no FDA-approved treatments for the disease.
Remedium Bio Inc. has entered into a multitarget research and development collaboration with Eli Lilly & Co. to advance gene therapies for type 2 diabetes and obesity using Remedium’s Prometheus dose-adjustable gene therapy platform.
RSS
